Abstract

Complement activation on cell surfaces leads to the massive deposition of C3b, iC3b, and C3dg, the main complement opsonins. Recognition of iC3b by complement receptor type 3 (CR3) fosters pathogen opsonophagocytosis by macrophages and the stimulation of adaptive immunity by complement-opsonized antigens. Here, we present the crystallographic structure of the complex between human iC3b and the von Willebrand A inserted domain of the α chain of CR3 (αI). The crystal contains two composite interfaces for CR3 αI, encompassing distinct sets of contiguous macroglobulin (MG) domains on the C3c moiety, MG1-MG2 and MG6-MG7 domains. These composite binding sites define two iC3b-CR3 αI complexes characterized by specific rearrangements of the two semi-independent modules, C3c moiety and TED domain. Furthermore, we show the structure of iC3b in a physiologically-relevant extended conformation. Based on previously available data and novel insights reported herein, we propose an integrative model that reconciles conflicting facts about iC3b structure and function and explains the molecular basis for iC3b selective recognition by CR3 on opsonized surfaces.

Complement activation on foreign cell surfaces leads to the generation of complement opsonins, which activate complement receptor type 3 (CR3) and pathogen clearance by macrophages. Here, the authors reveal structural basis of the interaction between human opsonin iC3b and the von Willebrand A inserted domain of the α chain of CR3.

Details

Title
The crystal structure of iC3b-CR3 αI reveals a modular recognition of the main opsonin iC3b by the CR3 integrin receptor
Author
Fernández, Francisco J 1   VIAFID ORCID Logo  ; Santos-López, Jorge 2 ; Martínez-Barricarte Rubén 3 ; Querol-García, Javier 1 ; Martín-Merinero Héctor 4   VIAFID ORCID Logo  ; Navas-Yuste, Sergio 2 ; Savko, Martin 5 ; Shepard, William E 5 ; Rodríguez de Córdoba Santiago 4   VIAFID ORCID Logo  ; Cristina, Vega M 2   VIAFID ORCID Logo 

 Agencia Estatal Consejo Superior de Investigaciones Científicas, Centro de Investigaciones Biológicas Margarita Salas, Madrid, Spain (GRID:grid.4711.3) (ISNI:0000 0001 2183 4846); Abvance Biotech srl, Madrid, Spain (GRID:grid.4711.3) 
 Agencia Estatal Consejo Superior de Investigaciones Científicas, Centro de Investigaciones Biológicas Margarita Salas, Madrid, Spain (GRID:grid.4711.3) (ISNI:0000 0001 2183 4846) 
 Agencia Estatal Consejo Superior de Investigaciones Científicas, Centro de Investigaciones Biológicas Margarita Salas, Madrid, Spain (GRID:grid.4711.3) (ISNI:0000 0001 2183 4846); Centro de Investigación Biomédica en Enfermedades Raras, Madrid, Spain (GRID:grid.4711.3); Vanderbilt University Medical Center, Division of Genetic Medicine, Department of Medicine, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916) 
 Agencia Estatal Consejo Superior de Investigaciones Científicas, Centro de Investigaciones Biológicas Margarita Salas, Madrid, Spain (GRID:grid.4711.3) (ISNI:0000 0001 2183 4846); Centro de Investigación Biomédica en Enfermedades Raras, Madrid, Spain (GRID:grid.4711.3) 
 L’Orme des Merisiers Saint-Aubin, Synchrotron SOLEIL, Gif-sur-Yvette, France (GRID:grid.426328.9) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2649422701
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.